T3D Therapeutics
Phase 2T3D Therapeutics, Inc. was founded in 2013 to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer’s disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer’s disease (AD). Additionally, T3D Therapeutics is targeting treatments for other other neurodegenerative diseases with an emphasis on Huntington’s Disease (HD).
About
T3D Therapeutics, Inc. was founded in 2013 to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer’s disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer’s disease (AD). Additionally, T3D Therapeutics is targeting treatments for other other neurodegenerative diseases with an emphasis on Huntington’s Disease (HD).
Funding History
2Total raised: $12M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile